BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bateson MC, Gedling P. Ursodeoxycholic acid therapy for primary biliary cirrhosis. A 10-year British single-centre population-based audit of efficacy and survival. Postgrad Med J 1998;74:482-5. [PMID: 9926123 DOI: 10.1136/pgmj.74.874.482] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Bateson. Hypergastrinaemia with long-term omeprazole treatment: LETTERS TO THE EDITORS. Alimentary Pharmacology & Therapeutics 1999;13:440-1. [DOI: 10.1046/j.1365-2036.1999.0467d.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
2 Poupon R. Management of primary biliary cirrhosis resistant to ursodeoxycholic acid therapy. Journal of Hepatology 2000;32:19-20. [DOI: 10.1016/s0168-8278(00)80438-9] [Cited by in Crossref: 7] [Article Influence: 0.3] [Reference Citation Analysis]
3 Gong Y, Huang ZB, Christensen E, Gluud C, Gong Y. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd000551.pub2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
4 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551. [PMID: 23235576 DOI: 10.1002/14651858.CD000551] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
5 Gish RG, Mason A. AUTOIMMUNE LIVER DISEASE. Clinics in Liver Disease 2001;5:287-314. [DOI: 10.1016/s1089-3261(05)70167-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
6 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 30.2] [Reference Citation Analysis]
7 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012;12:CD000551. [PMID: 23235576 DOI: 10.1002/14651858.CD000551.pub3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
8 Rannard A, Buck D, Jones DE, James OF, Jacoby A. Assessing quality of life in primary biliary cirrhosis. Clinical Gastroenterology and Hepatology 2004;2:164-74. [DOI: 10.1016/s1542-3565(03)00323-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
9 Prince MI, Jones DE. Primary biliary cirrhosis: new perspectives in diagnosis and treatment. Postgrad Med J 2000;76:199-206. [PMID: 10727561 DOI: 10.1136/pmj.76.894.199] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]